Speaker Profile
PhD, Founder, Chief Business Officer, BoD Member, Optellum Ltd.
Biography
Václav is a Founder and Board Director of Optellum (Oxford, UK), a lung health startup providing a AI-powered decision support platform that assists physicians in early diagnosis and optimal treatment of lung cancer, the first such software to secure FDA and CEMDR clearance, and CMS Medicare reimbursement under New Technology APC. Prior to founding Optellum he launched novel medical robotics devices as Global Product Manager at Hocoma, the global market leader in neurorehabilitation exoskeletons. Václav holds Oxford University Doctorate (D.Phil) in Machine Learning in collaboration with Siemens Healthineers and Mirada Medical, and Cambridge University M.Phil in Computational Biology. With his PhD supervisors (and later Optellum cofounders) Prof. Sir Mike Brady FRS and Dr. Timor Kadir they pioneered the application of computer vision to lung cancer therapy planning. He has worked and studied in eleven countries and speaks seven languages.
Talk
Enabling Early Diagnosis and Precision nmNSCLC Treatment with AI "Radiomics"
Lung cancer shows no symptoms until advanced stage. Automated analysis of 90M CT scans US patients receive p.a., such as emergency and cardiac studies, enables an "early identification system" to radically reshape outcomes. Leveraging powers of NLP and "Radiomics" to drive tiniest tumours into followup intervention, and deliver precision nmNSCLC treatment with targeted and immunotherapies.
AI and Data Sciences Showcase:
Optellum Ltd.
Optellum a lung health startup providing a AI-powered decision support platform that assists physicians in early diagnosis and optimal treatment of lung cancer, the first such software to secure FDA and CE-MDR clearance, and CMS Medicare reimbursement under New Technology APC.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
